Search results
Results from the WOW.Com Content Network
The drug — the brand name for the GLP-1 agonist semaglutide — “significantly reduced weekly alcohol craving,” according to a study published Wednesday, Feb. 12, in the Journal of the ...
There are three medicines approved by the US Food and Drug Administration for AUD, but fewer than 2% of people with the disorder receive treatment with them, Hendershot and his co-authors wrote in ...
“These drugs may sort of turn down the gain on the reward system in the brain, which then makes craving for food, alcohol, various types of drugs decrease,” he said.
Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research. The study was small — just 48 adults — and lasted just over two months, so it’s not the final word. Experts say it’s not yet clear how safe these drugs are for people who don’t need to lose ...
Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. [8] It has also been found effective in the treatment of other addictions and may be used for them off-label. [12]
In clinical studies, metadoxine has been reported to reduce the half-life of ethanol in healthy volunteers and in acutely intoxicated patients; to accelerate the metabolism of alcohol and acetaldehyde into less toxic higher ketones and to improve their urinary clearance; to restore laboratory variables such as alcohol, ammonia, γ-GT, and alanine aminotransferase; and to improve clinical ...
Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata. [1] It is a Janus kinase inhibitor selective for JAK1 and JAK2 . [ 2 ] Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor— baricitinib —for alopecia areata may vary depending on the population ...
The researchers concluded that GLP-1 receptor agonist medications—especially semaglutide—"offer promise as a novel treatment to reduce alcohol consumption and to prevent development of alcohol ...